4beta-hydroxycholesterol in Cirrhosis
Megadott ok: COVID pandemia and organisational changes hinder recruitment
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálat adatai
- Ki végzi
- University of Oulu
- Azonosító
- NCT04199910
- A regiszteradat frissítve
- 2026. május 5.
- Eredeti leírás
The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with spironolactone, patients treated with rifaximin, patients without spironolactone or rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its medications spironolactone and rifaximin are compared to control groups.A teljes eredeti leírásKevesebb
4beta-hydroksikolesteroli Maksakirroosissa
The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with spironolactone, patients treated with rifaximin, patients without spironolactone or rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its medications spironolactone and rifaximin are compared to control groups.
Bevonási feltételek: Patients with cirrhosis, pneumonia, Crohn's disease or colitis ulcerosa; Treated in the ward 42 of the Oulu University Hospital.
Kizáró feltételek: None.